Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07664631 · ClinicalTrials.gov registry record · Phase 1
Effects of Stimulant Medications in PTSD
A Phase 1 study, sponsored by University of Chicago.
- Not yet
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT07664631 is a Phase 1 study that has not yet begun recruiting, run by University of Chicago. The registered enrollment target is 40 participants.
The verdict
NCT07664631, a Phase 1 study, has not yet begun recruiting, sponsored by University of Chicago.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
While there have been advances in understanding post-traumatic stress disorder (PTSD) as a disorder and its biological features, unfortunately only one out of five traumatized persons with PTSD reach remission after cycling through evidence-based and/or FDA-approved medications. This is especially unfortunate given that people with PTSD are often from vulnerable populations, or those whose professions entail personal sacrifice. It is clear that new serotonergic antidepressants and atypical antipsychotics will not be sufficient to fix this gap, and new mechanisms of action need to be tested. In the current proposal, the investigators test the hypothesis that mixed amphetamine salts (brand name Adderall), FDA-approved for treating attention deficit hyperactivity disorder (ADHD), can improve PTSD outcomes.
Interventions
- DRUG Placebo
- DRUG Adderall
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2026-09-15 |
| Est. Completion | 2027-09-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07664631
The ClinicalTrials.gov registry entry for NCT07664631 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07664631 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07664631 about?
NCT07664631 is a clinical study titled "Effects of Stimulant Medications in PTSD". While there have been advances in understanding post-traumatic stress disorder (PTSD) as a disorder and its biological features, unfortunately only one out of five traumatized persons with PTSD reach remission after cycling through evidence-based and/or FDA-approved medications. This is especially u...
What is the current status of trial NCT07664631?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2026-09-15. Estimated completion is 2027-09-15.
What interventions are being tested in trial NCT07664631?
The interventions under investigation include: Placebo (DRUG), Adderall (DRUG).
Who is sponsoring clinical trial NCT07664631?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.